Tetrahydrouridine (THU)
(Synonyms: 四氢尿苷,NSC 112907, THU) 目录号 : GC34089Tetrahydrouridine (THU)是一种核苷类化合物，能够抑制Cytidine Deaminase（CDA）的活性，Ki=54nM。Tetrahydrouridine可降低尿苷和脱氧尿苷的水平，从而调节核苷酸代谢过程。
Cas No.:18771-50-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Tetrahydrouridine (THU) is a nucleoside compound that can inhibit the activity of Cytidine Deaminase (CDA), with a Ki of 54nM[1]. Tetrahydrouridine can reduce the levels of uridine and deoxyuridine, thereby regulating nucleotide metabolism[2]. Tetrahydrouridine is commonly used in studies analyzing cell cycle regulation mechanisms and DNA damage response mechanisms[3]. Tetrahydrouridine is also used in research exploring the mechanisms of cancer development[4].
In vitro, treatment of MIAPaCa-2, H441, and H1299 cell lines with Tetrahydrouridine (100μM) alone for 3 days significantly inhibits cell proliferation while reducing E2F1 protein levels and increasing the proportion of cells in the G1 phase[5]. Co-treatment of NAT1 knockout (KO) MDA-MB-231 breast cancer cells with Tetrahydrouridine (60μM) and 5-formyl-2'-deoxycytidine (5fdC; 4 or 40μM) for 3 days significantly inhibits Cytidine Deaminase activation and cytotoxicity induced by 5fdC[6].
In vivo, a combination of Tetrahydrouridine (4mg/kg) and Decitabine (0.2mg/kg) administered subcutaneously to C57BL/6 mice bearing melanoma xenografts twice a week. Tetrahydrouridine extends the in vivo retention time of Decitabine by inhibiting Cytidine Deaminase (CDA) activity, thereby enhancing the inhibitory effect on melanoma[7]. A combination of Tetrahydrouridine (10mg/kg) and Decitabine (0.1mg/kg and 1mg/kg) administered subcutaneously twice a week to C57BL/6 mice bearing ovarian cancer xenografts. Tetrahydrouridine enhances the inhibitory effect of Decitabine on ovarian cancer, significantly prolonging mouse survival and reducing tumor burden[8].
References:
[1] Xiang TX, Niemi R, Bummer P, et al. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition. J Pharm Sci. 2003 Oct;92(10):2027-39.
[2] Camiener GW. Studies of the enzymatic deamination of ara-cytidine. V. inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem Pharmacol. 1968 Sep;17(9):1981-91.
[3] Rijkers GT, Zegers BJ, Spaapen LJ, et al. Purine nucleoside phosphorylase (PNP) deficiency leading to accumulation of lymphocytes in S-phase. Pediatr Hematol Oncol. 1986;3(4):353-9.
[4] Hill B, Jagadeesh D, Pohlman B, et al. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Semin Hematol. 2021 Jan;58(1):35-44.
[5] Funamizu N, Lacy CR, Fujita K, et al. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.
[6] Hong KU, Tagnedji AH, Doll MA, et al. Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells. J Cancer Res Clin Oncol. 2023 Jul;149(8):5047-5060.
[7] Alcazar O, Achberger S, Aldrich W, et al. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012 Jul 1;131(1):18-29.
[8] Gomez S, Cox OL, Walker RR 3rd, et al. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer. J Immunother Cancer. 2022 Nov;10(11):e004974.
Tetrahydrouridine (THU)是一种核苷类化合物，能够抑制Cytidine Deaminase（CDA）的活性，Ki=54nM[1]。Tetrahydrouridine可降低尿苷和脱氧尿苷的水平，从而调节核苷酸代谢过程[2]。Tetrahydrouridine常被用于分析细胞周期调控机制以及DNA损伤响应机制的相关研究[3]。Tetrahydrouridine还被用于探索癌症发展机制的研究中[4]。
在体外，Tetrahydrouridine（100μM）单独处理MIAPaCa-2、H441和H1299细胞系3天，显著抑制细胞增殖，同时通过降低E2F1蛋白水平，增加G1期细胞比例[5]。Tetrahydrouridine（60μM）与5-甲酰基-2'-脱氧胞嘧啶（5fdC；4或40μM）共处理NAT1基因敲除（KO）的MDA-MB-231乳腺癌细胞3天，Tetrahydrouridine显著抑制了5fdC诱导的Cytidine Deaminase激活和细胞毒性[6]。
在体内，Tetrahydrouridine（4mg/kg）与Decitabine（0.2mg/kg）联合皮下注射于黑色素瘤异种移植C57BL/6小鼠，每周两次。Tetrahydrouridine通过抑制Cytidine Deaminase（CDA）活性，延长Decitabine的体内滞留时间，增强对黑色素瘤的抑制作用[7]。Tetrahydrouridine（10mg/kg）联合Decitabine（0.1mg/kg和1mg/kg）每周两次皮下注射，用于处理8卵巢癌异种移植C57BL/6小鼠。Tetrahydrouridine增强Decitabine对卵巢癌的抑制作用，显著延长小鼠生存期并减少肿瘤负荷[8]。
| Cell experiment [1]: | |
Cell lines | MIAPaCa-2 (human pancreatic carcinoma cell line), H441 (human lung carcinoma cell line), and H1299 (human lung carcinoma cell line) |
Preparation Method | MIAPaCa-2 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics (100mg/ml penicillin and 100mg/ml streptomycin) at 37°C in a humidified atmosphere of 95% air and 5% CO₂. H441 and H1299 cells were cultured in RPMI 1640 with the same supplements. Cells were treated with Tetrahydrouridine at a concentration of 100μM for 96 hours. |
Reaction Conditions | 100μM; 96h |
Applications | Tetrahydrouridine significantly reduced cell proliferation in MIAPaCa-2, H441, and H1299 cell lines. Tetrahydrouridine increased the rate of G1-phase occurrence while decreasing S-phase occurrence. Tetrahydrouridine also down-regulated E2F1 protein expression, which is associated with the G1/S transition, without affecting E2F1 mRNA levels. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Mice were subcutaneously injected with B16 melanoma cells (2 × 105 cells) to establish tumors. Mice were treated with Decitabine (0.2mg/kg) three times per week and Tetrahydrouridine (4mg/kg) twice per week, administered 30 minutes before Decitabine. |
Dosage form | 4mg/kg; s.c. |
Applications | The combination of Tetrahydrouridine and Decitabine inhibited tumor growth, increased the expression of melanocyte differentiation markers, and decreased the levels of cytokines that inhibit melanocyte differentiation. |
References: | |
| Cas No. | 18771-50-1 | SDF | |
| 别名 | 四氢尿苷,NSC 112907, THU | ||
| 化学名 | 3,4,5,6-tetrahydro-uridine | ||
| Canonical SMILES | O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1 | ||
| 分子式 | C9H16N2O6 | 分子量 | 248.23 |
| 溶解度 | 10mg/mL in DMSO, 16mg/ML in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.0285 mL | 20.1426 mL | 40.2852 mL |
| 5 mM | 805.7 μL | 4.0285 mL | 8.057 mL |
| 10 mM | 402.9 μL | 2.0143 mL | 4.0285 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: ≥95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet